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Abstract. 
 
All mammalian cells absolutely require poly-
 
amines (putrescine, spermidine, and spermine) for growth.
 
Here we show that the overexpression of cDNA for
 
S
 
-adenosylmethionine decarboxylase (AdoMetDC),
the main regulatory enzyme in the biosynthesis of
 
higher polyamines, induces transformation of rodent
ﬁbroblasts when expressed in the sense or the antisense
orientation. Both transformants were able to induce in-
vasive tumors in nude mice. Neither transformation
was associated with activation of the mitogen-activated
protein kinases Erk1 and Erk2. Instead, the AdoMet
DC sense, but not antisense, transformants displayed
 
constitutive activation of the c-Jun NH
 
2
 
-terminal kinase
(JNK) pathway. However, both transformations con-
verged on persistent phosphorylation of endogenous
c-Jun at Ser73. The phenotype of the AdoMetDC sense
transformants was reversed by expression of dominant-
negative mutants of SEK1 (MKK4), JNK1, and c-Jun
(TAM-67), which were also found to impair cytokinesis.
Similarly, TAM-67 reverted the morphology of the
AdoMetDC-antisense expressors. This report is the ﬁrst
demonstration of a protein whose overexpression or
block of synthesis can induce cell transformation. In ad-
dition, we show that the polyamine biosynthetic en-
zymes require c-Jun activation for eliciting their biolog-
ical effects.
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Introduction
 
The polyamines putrescine, spermidine (spd), and sper-
mine are essential for cell proliferation (Tabor and Ta-
bor, 1984; Pegg, 1988; Heby and Persson, 1990; Cohen,
1998). In cells stimulated to grow and divide, the syn-
thesis of polyamines is always rapidly induced. The pre-
cise physiological functions of polyamines have re-
mained elusive, even though they have been shown to
interact with and stabilize negatively charged macro-
molecules, such as nucleic acids and phospholipids, and
 
to
 
 
 
stimulate the synthesis of DNA, RNA, and proteins
(Tabor and Tabor, 1984; Pegg, 1988; Heby and Persson,
1990; Cohen, 1998).
Polyamines also seem to be involved in the process of
 
cell transformation. Ornithine decarboxylase (ODC),
 
1
 
the first enzyme in polyamine biosynthesis, has thus far
been the main focus of interest. ODC is known to be-
come activated after treatment with chemical carcino-
gens and tumor promoters, as well as in cells transformed
by various oncogenes, such as v
 
-src
 
, 
 
neu
 
, 
 
myc
 
, and 
 
ras
 
(Pegg, 1988; Auvinen et al., 1992). Furthermore, ODC is
a direct transcriptional target of c-Myc (Bello-Fernandez
et al., 1993) and has oncogenic potential when overex-
pressed (Auvinen et al., 1992, 1997; Clifford et al., 1995;
O’Brien et al., 1997).
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S
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-terminal kinase; MAPK, mitogen-activated
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Here, we examined whether 
 
S
 
-adenosylmethionine de-
carboxylase (AdoMetDC; EC 4.1.1.50), the other key reg-
ulatory enzyme in polyamine biosynthesis (Tabor and Ta-
bor, 1984; Pegg, 1988; Heby and Persson, 1990; Cohen,
1998), might also be involved in cell transformation.
AdoMetDC catalyzes the formation of decarboxylated
 
S
 
-adenosylmethionine, which serves as an aminopropyl
donor in the biosynthesis of spd and spermine, which are
vital for cell growth. Like ODC, AdoMetDC has a fast
turnover rate, and is rapidly induced up to tenfold and
higher in various normal and neoplastic growth processes
(Cohen, 1998). Furthermore, inhibition of AdoMetDC by
various drugs has been found to have antiproliferative and
antitumor activity (Pegg and McCann, 1992; Regenass et
al., 1994) and inhibits metastasis (Gutman et al., 1995).
However, there has not been direct evidence for a specific
role of AdoMetDC in transformation.
Cell transformation is thought to result from aberrant
activation of signal transduction molecules that control
cell proliferation (Weinberg, 1996). Most studies have sug-
gested that the Ras-Raf-mitogen-activated protein kinase
(MAPK) pathway (Seger and Krebs, 1995) plays a major
role in transformation. Indeed, many oncogenes, including
 
ras
 
, 
 
src
 
, 
 
raf
 
, and 
 
mos
 
, have been shown to exert their effect
through the activation of MAPKs Erk1 and Erk2 (Howe
et al., 1992; Samuels et al., 1993; Okazaki and Sagata,
1995). However, recent studies have indicated that the ac-
tivation of Erks is not invariable, and a parallel pathway,
the c-Jun NH
 
2
 
-terminal kinase (JNK) pathway, may be ac-
tivated instead (Raitano et al., 1995; Crespo et al., 1996;
Clark et al., 1997; Rodrigues et al., 1997). The major target
of JNKs is c-Jun, which becomes phosphorylated on Ser63
and Ser73 and thereby becomes activated (Su and Karin,
1996; Ip and Davis, 1998). Here, we report that overex-
pression of AdoMetDC causes full transformation of ro-
dent fibroblasts, and it is capable of inducing highly inva-
sive tumors in nude mice, and these transformed cells
show constitutive activation of JNKs and phosphorylation
of c-Jun on Ser73. Expression of dominant-negative mu-
tants of the upstream kinases of c-Jun (DN SEK1 and DN
JNK1) and the transcriptionally inactive mutant of c-Jun,
TAM67, reversed the transformation and impaired cytoki-
nesis, yielding polykaryotic cells. Paradoxically, tumori-
genic transformation was also seen in cells expressing the
AdoMetDC cDNA in the antisense orientation. This
transformation, again, appeared to involve the phosphory-
lation of c-Jun, but did not involve JNK activation.
 
Materials and Methods
 
AdoMetDC Vector Constructions and Transfections
 
A 1.65-kb insert of human AdoMetDC cDNA was isolated from pSAMh1
(Pajunen et al., 1988) with PvuII/BamHI digestion, resulting in a shorter
5
 
9
 
-untranslated region than the full-length cDNA. The fragment was
blunt-ended, ligated to SalI linkers, and inserted in both orientations into
the SalI site of the pLTRpoly vector (American Type Culture Collection
77109). The sense and antisense constructs and the empty vector (control)
were transfected together with a 
 
neo
 
-selection marker (pSV2
 
neo
 
) into
cells using LipofectAMINE (GIBCO BRL). The transfected cells were se-
lected for resistance to G418 (GIBCO BRL) (400 
 
m
 
g/ml) for two weeks.
The transfections were repeated four times. To avoid problems with
clonal variation, the data are from a total pool of the transfectants.
 
Cell Culture
 
The NIH3T3 cells (American Type Culture Collection), their stable deriv-
atives expressing 
 
neo
 
 and the empty pLTRpoly vector (4N), and
AdoMetDC in sense (Amdc-s) or antisense (Amdc-as) orientations were
cultured in DME supplemented with antibiotics and 5% newborn calf se-
rum (GIBCO BRL) or FCS (Bioclear). Spermidine at a low concentration
(1 
 
m
 
M), was added to parallel Amdc-as cell cultures (Amdc-as 
 
1 
 
spd) to
prevent the counter selection of cells expressing the AdoMetDC-as
mRNA at levels that would block the synthesis of vital higher polyamines.
The corresponding Rat-1 cell transfectants were grown similarly.
 
Northern Blotting
 
Polyadenylated mRNA was isolated by oligo(dT) cellulose chromatogra-
phy from 5–10 
 
3
 
 10
 
7
 
 cells. RNA samples (8 
 
m
 
g) were size-fractionated in
agarose gels, transferred to Hybond-N nylon filters (Amersham Phar-
macia Biotech), and hybridized with specific probes, as described previ-
ously (Paasinen-Sohns and Hölttä, 1997). [
 
32
 
P]dCTP-labeled probes for
AdoMetDC (PvuII/BamHI fragment of pSAMh1) and ODC (HindIII
fragment of pODC16) were generated using a multiprime DNA-labeling
kit (Amersham Pharmacia Biotech).
 
Assay of AdoMetDC and ODC Activities
 
The activities of AdoMetDC and ODC were assayed by measuring the
production of 
 
14
 
CO
 
2
 
 from 
 
S
 
-adenosyl-
 
L
 
-(carboxyl-
 
14
 
C)methionine or 
 
L
 
-(1-
 
14
 
CO
 
2
 
)ornithine (Cohen, 1998), respectively.
 
Analysis of Polyamines
 
Polyamine concentrations in the cells were measured with a Hewlett-
Packard HP 1090 liquid chromatograph with fluorescence detection
(Hyvönen et al., 1992).
 
Staining of Actin Filaments
 
The cells grown on glass coverslips were fixed with 3.5% paraformalde-
hyde, permeabilized with 0.2% NP-40, and stained with rhodamine-conju-
gated phallacidin.
 
Soft Agar Growth
 
5 
 
3
 
 10
 
4
 
 cells, in growth media, were mixed with agar, resulting in a 0.35%
agar-containing mixture, and laid over a 0.7% bottom agar layer. The cells
were grown for four weeks, and growth media was added on to the top
agar twice a week.
 
Tumorigenicity Assay
 
Nude
 
 mice (
 
nu/nu
 
-BALB/cABom, female) were obtained from Bomholt-
gaard Breeding and Research Center, Ltd., and the tumorigenicity assays
were performed at Orion-Farmos Experimental Cancer Research Center.
The animals were maintained in a barrier unit, and all materials that came
into direct contact with the mice were autoclaved. The control (4N),
Amdc-s, Amdc-as, and Amdc-as
 
1
 
spd cells were injected subcutaneously
into both flanks of the mice (10
 
7
 
 cells/injection site, five mice/cell line).
The occurrence of tumors was followed regularly for 62 d.
 
Cell Lysates, Nuclear Fractions, and Western Blots
 
Cell lysates and nuclear fractions were prepared essentially as described
previously (Paasinen-Sohns and Hölttä, 1997). In brief, to isolate deter-
gent soluble proteins, the cells were lysed in 1% Triton X-100 containing
buffer, and the nuclei were removed by centrifugation. For nuclear frac-
tions, the cells were suspended in hypotonic lysis buffer containing 0.5%
NP-40, the nuclei were collected by centrifugation at maximal speed in an
Eppendorf microcentrifuge for 20 s, washed in lysis buffer, resuspended,
and sonicated. After determining protein concentrations, the samples
were suspended in Laemmli’s sample buffer, resolved by SDS-PAGE, and
immunoblotted, as detailed before (Paasinen-Sohns and Hölttä, 1997).
Erks were detected by mAbs to Erk1/Erk2 (Zymed Laboratories). Phos-
phorylated c-Jun, dominant-negative mutants of JNK1 and SEK1, and
truncated c-Jun (TAM67) proteins were immunoblotted with pAbs to
phospho-c-Jun(Ser73) (New England Biolabs, Inc.), JNK1(FL) (Santa 
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Cruz Biotechnology, Inc.), SEK1/MKK4 (Sigma-Aldrich), and c-Jun/AP-1
(Ab-1) (Calbiochem-Novabiochem), respectively.
 
Assay of MAPK Activity
 
1 mg of soluble proteins was immunoprecipitated with 
 
a
 
-rat MAPK R2
pAb (Upstate Biotechnology). The immunocomplex activity was measured
in a 25-
 
m
 
l volume of kinase buffer (Paasinen-Sohns and Hölttä, 1997) con-
taining 50 
 
m
 
M ATP, 5 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP (3,000 Ci/mmol) (NEN Life Science
Products), and 25 
 
m
 
g MAPK substrate peptide (APRTPGGRR) (Upstate
Biotechnology) at 30
 
8
 
C for 15 min (Paasinen-Sohns and Hölttä, 1997).
 
Assay of JNK Activity
 
Immunocomplex assay of JNK activity was performed using the 
 
a
 
-JNK1
(C-17; Santa Cruz Biotechnology, Inc.) antibody and c-Jun(1-169)–GST
fusion protein (Upstate Biotechnology) as the substrate (Paasinen-Sohns
and Hölttä, 1997). For the solid-phase JNK kinase assay (Hibi et al.,
1993), cells were lysed in buffer containing 20 mM Hepes, pH 7.7, 0.3 M
NaCl, 2.5 mM MgCl
 
2
 
, 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM DTT,
20 mM 
 
b
 
-glycerophosphate, 0.1 mM Na
 
3
 
VO
 
4
 
, 2 
 
m
 
g/ml aprotinin/leupeptin,
and 100 
 
m
 
M AEBSF, and the extracts were diluted to 75 mM NaCl. 1 mg
of protein extracts was mixed with 2.5 
 
m
 
g of agarose-conjugated c-Jun(1-
169)–GST fusion protein (Upstate Biotechnology) to affinity purify the
JNKs. For the kinase reactions, the beads were suspended in 25 
 
m
 
l of the
kinase assay buffer supplemented with 50 
 
m
 
M ATP and 5 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP
(3,000 Ci/mmol) (NEN Life Science Products). After a 20-min incubation
at 30
 
8
 
C, the phosphorylated proteins were analyzed by 12.5% SDS-PAGE
and autoradiography.
 
Dominant-Negative SEK/JNK/c-Jun
Mutant Transfections
 
Normal 4N- and AdoMetDC-transformed Amdc-s cells were transfected
with 3 
 
m
 
g of empty pcDNA3-vector, DN SEK1 (SEK1[AL]) (Yan et al.,
1994), or DN JNK1 (FLAG-JNK1[APF]) plasmids (Dérijard et al., 1994),
together with a pBabe Puro selection marker (Morgenstern and Land,
1990) using LipofectAMINE PLUS (GIBCO BRL). Similarly, pCMV-
vector or c-Jun-mutant pCMV-TAM67 (Brown et al., 1993), which was
deleted at the NH
 
2
 
-terminal, together with a selection marker pZeoSV2/
 
lacZ
 
 (Invitrogen), were transfected. 3 
 
m
 
g/ml
 
 
 
puromycin (Sigma-Aldrich)
or 250 
 
m
 
g/ml of Zeocin (Invitrogen) were added to the corresponding cul-
tures 2 d after transfection.
 
Results
 
Overexpression of AdoMetDC cDNA in Sense or 
Antisense Orientation Causes Cell Transformation
 
To study the consequences of overexpression of
AdoMetDC on growth regulation, we cloned the human
AdoMetDC cDNA (truncated at the 5
 
9
 
-untranslated re-
gion to remove sequences that inhibit translation) into a
pLTRpoly expression vector, both in sense and antisense
orientations. The constructs were transfected with a 
 
neo
 
selection marker (pSV2
 
neo
 
) into mouse NIH3T3 cells and
Rat-1 fibroblasts, and stable cell lines were generated. The
control NIH3T3 cells transfected with pLTRpoly and
pSV2
 
neo
 
 vectors (4N) exhibited an epithelioid morphol-
ogy, stringent density-dependent growth (Fig. 1 A, a), nor-
mal actin filaments (Fig. 1 A, d), and did not grow in soft
agar (only 1.7% of the cells formed tiny colonies) (Fig. 1 A,
g). Transfection of NIH3T3 cells with the AdoMetDC
sense construct resulted in a complete morphological
transformation. The transfectants displayed an elongated
morphology, grew without contact inhibition in a criss-
cross manner, and formed innumerable foci in tissue cul-
ture (Fig. 1 A, b). They also showed disintegrated actin fil-
Figure 1. (A) Morphology, actin filaments, and soft agar
growth of NIH3T3 cells overexpressing human AdoMetDC
cDNA in sense (Amdc-s) and antisense (Amdc-as) orienta-
tions are shown. (a, d, and g) Parental NIH3T3 cells trans-
fected with the neomycin resistance gene and the empty
pLTRpoly vector (control, 4N), (b, e, and h) Amdc-s cells and
(c, f, and i) Amdc-as cells grown with 1 mM spermidine
(Amdc-as1spd) in tissue cultures (a–c), stained for actin fila-
ments (d–f), and grown in soft agar (g–i). (B) Morphology of
Rat-1 cell transfectants. (a–c) Rat-1 control cells and transfec-
tants expressing AdoMetDC sense and antisense constructs.
Rat-1 Amdc-as cells were grown in the presence of spermi-
dine, as described above. 
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aments (Fig. 1 A, e) and acquired the ability to grow in soft
agar (15.2% of the cells formed large foci) (Fig. 1 A, h).
Surprisingly, the same was true for the AdoMetDC anti-
sense construct–expressing cells when they were cultured
in the presence of spd (1 
 
m
 
M) (Fig. 1 A, c). Exogenous
spermidine had to be added to keep alive the high Amdc-
as expressors, which are blocked in the synthesis of spermi-
dine. However, the Amdc-as
 
1
 
spd cells displayed a less
elongated morphology than the Amdc-s cells, but showed a
similar degree of disintegration of the actin filaments (Fig.
1 A, f) and growth in soft agar (19.1%). The Amdc-as cells
grown in the absence of spermidine (except what is pro-
vided by serum in the growth media) exhibited a much
lower degree of morphological transformation with partial
disintegration of the actin filaments. Similar inductions of
 
transformation by the AdoMetDC sense and antisense
constructs were also seen in Rat-1 cells. Fig. 1 B, a shows
the morphology of normal Rat-1 control cells, and Fig. 1 B,
b and c, show the transformed phenotype induced by the
AdoMetDC sense and antisense constructs (with spermi-
dine supplementation), respectively. Spermidine had no
effect on the morphology of normal 4N cells or Amdc-s
cells. Overexpression of AdoMetDC was not associated
with increased proliferation or cell death (data not shown),
thus AdoMetDC is specifically associated with morpholog-
ical transformation. The data presented below are mostly
from experiments with NIH3T3 cells, but also hold true for
Rat-1 cells.
 
Human AdoMetDC Expression and Polyamine Levels 
in NIH3T3 Transfectants
 
Northern blot analyses showed that the normal 4N cells
expressed low levels of two endogenous mouse Ado
MetDC mRNAs (Pajunen et al., 1988). The 3.1-kb mRNA
was expressed at a higher level than the 2.1-kb species,
which was visible only upon longer exposure (Fig. 2
A). The Amdc-s cells carrying the human AdoMetDC
sense construct expressed high levels of two AdoMetDC
mRNAs of 1.65 kb and 2.65 kb, which are the sizes
predicted for the use of polyadenylation signals in
AdoMetDC cDNA (Pajunen et al., 1988) and in the
pLTRpoly vector, respectively. The Amdc-as cells carry-
ing the antisense construct also expressed the 2.65-kb
mRNA of expected size, but the most prominent band was
of a slightly smaller size (Fig. 2 A). This smaller mRNA
likely arises as a result of splicing out 0.3-kb vector se-
quences, as there is a consensus splice donor site at the end
of the AdoMetDC antisense cDNA and a splice acceptor
site in the vector. The Amdc-as
 
1
 
spd cells had higher lev-
els of AdoMetDC antisense mRNAs, as expected (see
above). No appreciable changes in the expression level of
the AdoMetDC mRNAs were detected in normal or
Amdc-s cells cultured with spermidine.
Amdc-s cells had a 30–40-fold higher constitutive
AdoMetDC activity (ranging from a 15–60-fold increase in
four independent transfection experiments), compared
with the parental cell line (Fig. 2 B,
 
 
 
left). In these experi-
ments, the fold of increase in the AdoMetDC activity
seemed to correlate with the degree of morphological
transformation. Growing the cells with 1 
 
m
 
M spermidine
had no marked effect on the AdoMetDC activity. The ac-
tivity of ODC was not altered in the Amdc-s cells cultured
with or without spermidine. Thus, there is no feed-back re-
pression of polyamine biosynthetic enzymes (Tabor and
Tabor, 1984; Pegg, 1988; Heby and Persson, 1990; Cohen,
1998) at this low concentration of spermidine. The Amdc-
as cells had a slightly lower activity of AdoMetDC than
normal cells, but showed an increase in ODC activity,
especially in cultures supplemented with spermidine
(
 
z
 
12-fold) (Fig. 2 B, right). This increase in ODC activity,
which appeared to be mainly posttranscriptional (data
not shown), may be a compensatory mechanism. As
AdoMetDC is the rate-limiting enzyme for the vital higher
polyamines, the Amdc-as cells apparently try to keep alive
by increasing ODC, and thus putrescine (a polyamine pre-
cursor), production (Fig. 2 C). No appreciable changes
were observed in spermidine or spermine synthase activi-
ties in any of these transfectants (data not shown).
Figure 2. Expression of human AdoMetDC cDNA, the activities
of AdoMetDC and ODC, and polyamine contents in NIH3T3
transfectants are shown. (A) The Northern blot shows the ex-
pression levels of AdoMetDC mRNA in transfected cells. The in-
tegrity and loading of RNA was controlled by hybridizing the
blot with human b-actin c-DNA. Note, the consistent lower b-actin
signal in the Amdc-as cells may also reflect their retarded growth
rate. The size of the mRNAs are indicated in kb on the left. (B)
AdoMetDC (left) and ODC (right) activities were measured as
described in Materials and Methods. Dotted bars, cells grown
without spermidine addition; striped bars, cells grown with sper-
midine. (C) The amount of polyamines is expressed as pmol/mg
DNA. Acetylated polyamines were not detected. Black bars, pu-
trescine; gray bars, spermidine; striped bars, spermine. The enzy-
matic activities and the polyamine contents were determined
from parallel dishes after 2 d of culture. The results are represen-
tative of four independent experiments. 
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The amounts of spermidine and spermine were roughly
the same in the 4N control and Amdc-as cells cultured for
two or three days (Fig. 2 C). The Amdc-as
 
1
 
spd cells had
increased putrescine levels due to ODC induction (see
above), a block of the synthesis of spermidine from pu-
trescine, or retroconversion of spermidine to putrescine.
Other polyamines were not greatly affected. Generally,
the polyamine pattern in Amdc-as
 
1
 
spd cells was similar
to that of cells transformed by the overexpression of ODC
(Auvinen et al., 1997). However, the increase in putrescine
in the Amdc-as
 
1
 
spd cells was severalfold lower than that
in the ODC-transformed cells, which, because of uninhib-
ited AdoMetDC, also converted the excessive putrescine
to spermidine. In the Amdc-s cells, the polyamine compo-
sition was very different. The level of spermidine was only
one fourth, and the level of spermine was about twice as
high, compared with normal or Amdc-as cells. The content
of putrescine in the Amdc-s cells was very low or not de-
tectable (Fig. 2 C).
 
Inoculation of AdoMetDC-overproducing Cells into 
Nude Mice Induces Rapidly Growing, Highly
Invasive Tumors
 
To study the potential tumorigenicity, AdoMetDC-over-
expressing cells were injected into athymic nude mice in
both flanks. It should be noted that all extracellular fluids
contain polyamines in low (micromolar) concentrations
(Scalabrino and Ferioli, 1982; Cohen, 1998). All inocula-
tions (10 out of 10 in each case) with the three transformed
cell lines gave rise to tumors. Interestingly, the Amdc-s
and Amdc-as
 
1
 
spd cells, particularly the former, induced
aggressive growing, invasive tumors that were able to pen-
etrate rapidly through the muscle and fat tissues into the
peritoneal cavity. The mice exposed to the Amdc-s or
Amdc-as
 
1
 
spd cells died or had to be killed 10–15 d after
the inoculation. The Amdc-as cells, cultured in the ab-
sence of exogenous spermidine, also induced tumor for-
mation, but only at the sites of inoculation and over a
longer period of time (
 
z
 
4 wk). The mice that received
normal 4N cells, were followed to 62 d, and during this ex-
tended follow up, they developed, on occasion, small, non-
invasive tumors (in 3 out of 10 inoculations).
 
Erk1 and Erk2 Are Not Constitutively Activated in 
AdoMetDC-transformed Cells
 
Numerous reports indicate that activation of the Erk1/Erk2
MAPK cascade is necessary for cell growth. Since MAPK is
activated in cells transformed by many oncogenes (Howe et
al., 1992; Samuels et al., 1993; Okazaki and Sagata, 1995), we
tested whether MAPK might also be constitutively activated
and responsible for the transformed phenotype in Amdc-s
and Amdc-as
 
1
 
spd transformants. To distinguish between
the inactive and active states of Erk1 and Erk2 proteins, we
starved the normal cells (4N and Rat-1) with 0.5% FBS for
20 h, and then stimulated the cells with PDGF-BB (30 ng/ml)
for 15 min at 37
 
8
 
C. Exposure to PDGF-BB resulted in dis-
tinct shifts of Erk1 and Erk2 migration, as expected (Fig. 3
A). No shifts of Erks, indicative of constitutive activation,
were detected in the transformants that were grown normally
in the presence of serum (Fig. 3 A). Additionally, MAPK ac-
tivities were measured by in vitro immunocomplex kinase as-
says, which used a synthetic peptide of myelic basic protein as
a substrate. The normal 4N cells responded to PDGF-BB
with a threefold activation, and Rat-1 cells exhibited a 15-fold
increase in MAPK activity (Fig. 3 B). Again, neither the
NIH3T3 nor Rat-1 transformants displayed a constitutive in-
crease in MAPK activity (Fig. 3 B).
Figure 3. Erk1 and Erk2 are not constitutively activated in
AdoMetDC transformants. (A) Western blot analysis of the
phosphorylation status of Erks. The electrophoretic mobilities of
Erk1 and Erk2 in Amdc-s or Amdc-as1spd cells did not display
upshifts of protein bands (in 12.5% SDS-PAGE) that were seen
in control cells (4N and Rat-1) stimulated with PDGF-BB. (B) In
vitro immunocomplex kinase assays showed a clear stimulation
of MAPK activity in PDGF-BB–stimulated control cells, but no
constitutive upregulation was detected in AdoMetDC transfor-
mants. Gray bars, cells starved for 24 h in 0.5% serum; white
bars, starved cells stimulated with PDGF-BB for 15 min at 378C;
black bars, cells grown normally in 5% serum.
Figure 4. Endogenous JNK is constitutively activated in
AdoMetDC-overexpressing NIH3T3 and Rat-1 cells, resulting in
increased phosphorylation of c-Jun at Ser73. (A) The JNKs were
purified by virtue of their binding to agarose-conjugated GST-
c-Jun. The autoradiograms show the phosphorylation status of
GST-c-Jun used as the substrate in the solid-phase kinase assays.
(B) Western blots from the nuclear extracts show a strong phos-
phorylation of c-Jun at Ser73 in AdoMetDC transformants. The
bottom rows show the total amount of c-Jun in nuclear extracts.
The levels of JunD and ATF-2 remained constant and were used
as loading controls (data not shown).The Journal of Cell Biology, Volume 151, 2000 806
Endogenous JNK Is Activated in the AdoMetDC Sense, 
but Not Antisense, Transformants
As AdoMetDC transformation appeared not to be linked
to Erk1/Erk2 activation, we analyzed the activity of the
JNKs. These kinases were originally described as stress-
induced kinases, but have been recently connected to on-
cogenesis, as well (Raitano et al., 1995; Rodrigues et al.,
1997). Interestingly, the JNK kinase activity was 5–9-fold
higher in NIH3T3 Amdc-s cells than in control cells, with
the Amdc-as1spd cells displaying no significant increase,
as analyzed by the solid-phase assay (Fig 4 A) or the im-
munocomplex kinase assay (data not shown). Also the
transient transfection of AdoMetDC cDNA into NIH3T3
cells resulted in increased JNK activity (data not shown),
indicating that the activation of JNK in Amdc-s cells is not
just secondary to transformation. p38 MAPK was not acti-
vated in these cells, as confirmed by phosphospecific anti-
body blots (data not shown).
AdoMetDC-transformed Cells Display a Constitutive 
Increase in Phosphorylation of c-Jun at Ser73
Transcriptional activity of c-Jun is regulated by phosphor-
ylation of its NH2-terminal transactivation domain at
Ser73 (and Ser63 as a minor site) (Binétruy et al., 1991;
Smeal et al., 1991, 1992). Both the Amdc-s and Amdc-
as1spd cells, grown normally in the presence of serum,
displayed a distinctive, constitutive phosphorylation of
c-Jun on Ser73, whereas the normal control cells did not
show any significant amount of phosphorylated c-Jun, as
blotted with an antibody specific for c-Jun carrying phos-
phoserine at position 73 (Fig. 4 B). The cellular level of
c-Jun was elevated to some extent in the AdoMetDC-
transformed cells, compared with normal cells (Fig. 4 B).
This could be explained by an increased expression of
c-Jun through autoactivation (Su and Karin, 1996) or by
phosphorylation of c-Jun at Ser63 and Ser73, which stabi-
lizes the protein (Musti et al., 1997).
The Dominant-Negative Mutants of the JNK Pathway 
Reverse the Transformed Morphology and Interfere 
with Cytokinesis of the AdoMetDC Sense Expressors
Previous studies with Ras-transformed cells have indi-
cated that c-Jun becomes transcriptionally activated by the
phosphorylation of Ser63 and Ser73 (Smeal et al., 1991),
and the transactivation domain of c-Jun is required for
transformation by ras in NIH3T3 cells (Westwick et al.,
1994) and for cotransformation of rat embryo fibroblasts
(Alani et al., 1991). The cascade leading to these phos-
phorylations includes consecutive activation of the kinases
SEK1/MKK4 or MKK7 (immediate upstream activators
of JNKs) and the JNKs 1 and 2 (Su and Karin, 1996; Ip and
Davis, 1998). We tested the effects of dominant-negative
mutants of SEK1, JNK1, and TAM-67, lacking the trans-
Figure 5. The transformed morphology of AdoMetDC-overexpressing cells is reversed by the expression of dominant-negative mutants
of SEK1, JNK1, and c-Jun (TAM-67). (A) The morphology of (a) Amdc-s cells was changed to a more flattened and normal-looking
phenotype by expressing (b) DN SEK1, (d) DN JNK1, and (f) TAM67 and resulted in the formation of multinucleated, growth-arrested
cell populations, indicative of cytokinetic failure, in all three transfections (c, e, and g). The cells were transfected with mutant plasmids
and selection markers, grown in the presence of zeosin or puromycin for 10 d (b, d, and f) or 17–21 d (c, e, and g), and photomicro-
graphed. (B) The transformed morphology of Amdc-as1spd cells is reversed by c-Jun mutant TAM67. The cells were transfected as de-
scribed above. (C) The ability of the Amdc-s and Amdc-as1spd cells to grow in soft agar is inhibited by TAM67 expression. In both cell
lines the inhibition of soft agar growth by TAM67 was .90%, and the colonies formed were tiny in size.Paasinen-Sohns et al. Cell Transformation Induced by AdoMetDC 807
activation domain of c-Jun, on AdoMetDC-transformed
cells. The plasmids containing the mutants or the control
vectors were transfected together with a selection marker
(zeo or puro) into the 4N cells and Amdc-s cells (Fig. 5 A,
a). Transfections of the control vectors did not elicit any
morphological changes in either cell type. In contrast, ex-
pression of dominant-negative mutants of SEK1 and
JNK1 in Amdc-s cells led to a reversion towards the nor-
mal, epithelioid phenotype (Fig. 5 A, b and d) and pro-
duced multinucleated cells in subsequent cell divisions
(Fig. 5 A, c and e). Expression of TAM67 resulted in the
most efficient reversion of the transformed phenotype of
Amdc-s cells to normal (Fig. 5 A, f) and formation of flat
multinucleated cells, as well (Fig. 5 A, g). The reversal was
not due to TAM67 interfering nonspecifically with the ex-
pression of AdoMetDC, as verified by the continued ele-
vation in AdoMetDC activity. Also the phenotype of
Amdc-as1spd cells was reverted by TAM67 expression
(Fig. 5 B, a and b), but DN SEK1 and DN JNK1 mutants
did not appear to be effective (data not shown). The mu-
tants had no visible effect on the morphology of normal
cells. The reversal of transformation by TAM67 expres-
sion was also seen in soft agar growth of the transfected
cell lines (Fig. 5 C). In both Amdc-s (Fig. 5 C, a) and
Amdc-as1spd cells (Fig. 5 C, c), TAM67 expression mark-
edly reduced the size and amount of the colonies (Fig. 5 C,
b and d). To confirm the expression of the mutants, cell ly-
sates were analyzed for mutant proteins by Western blot-
ting (Fig. 6, A and B). It is also notable that the expression
of DN JNK1 and DN SEK1 mutants in Amdc-s cells mark-
edly inhibited c-Jun phosphorylation (Fig. 6 C).
Discussion
Here, we found that overexpression of human AdoMetDC
induces transformation in NIH3T3 and Rat-1 cells, and it
is tumorigenic in nude mice. Interestingly, AdoMetDC ap-
pears to be a more potent inducer of transformation than
ODC (Auvinen et al., 1992) (this study and data not
shown). Considering this, it is important to keep in mind
that many human cancers show elevated AdoMetDC ac-
tivity, though to a lesser level than ODC (Scalabrino and
Ferioli, 1982; Meyeskens and Gerner, 1999). However, it is
notable that activation of AdoMetDC in the cancer cells in
vivo may be a much more common event than is currently
thought by the in vitro enzyme assays performed in the
presence of exogenous putrescine (the activator of mam-
malian AdoMetDC). Indeed, besides through enhanced
expression, the AdoMetDC activity may be increased due
to an elevation of endogenous putrescine, as a result of the
activation of ODC (and other means). Therefore, we
should perhaps reassess the earlier reported increases and
possible role of AdoMetDC in cancer development.
Previous studies have suggested that an increase in pu-
trescine is specifically connected to cell proliferation and
malignant transformation (Clifford et al., 1995; Auvinen
et al., 1997; O’Brien et al., 1997). This idea is in line with
our results for the Amdc-as1spd transformants, which
show an enhanced ODC activity and elevated putrescine
content, that is, a similar polyamine pattern than the
ODC-transformed cells (Auvinen et al., 1997). However,
our results on AdoMetDC-induced transformation ques-
tion the unconditional importance of putrescine in dysreg-
ulated growth, as the Amdc-s cells had very low levels of
putrescine and the polyamine balance was strongly to-
ward the end product, spermine. Considering the opposite
patterns of total polyamines in the cells transformed by ei-
ther AdoMetDC (this study) or ODC (Auvinen et al.,
1997), it seems that an imbalanced ratio of polyamines,
rather than a single polyamine change, may lead to cell
transformation.
The tumorigenicity assays revealed that all three cell
lines, Amdc-s, Amdc-as, and Amdc-as1spd with a trans-
formed morphology in vitro, were also capable of produc-
ing tumors in nude mice. Intriguingly, the Amdc-s cells
gave rise to highly invasive tumors. The tumor cells tra-
versed rapidly from the site of inoculation into the perito-
neal cavity. Thus, the AdoMetDC-overexpressing cells
seem to possess a more invasive activity than the ODC-
overexpressing cells that were found to invade only the
neighboring striated muscle and fat tissues (Auvinen et al.,
1997). The mechanisms behind the remarkable tumorige-
nicity and invasiveness of the AdoMetDC-overexpressing
cells are under investigation. As single genes are not
known to induce oncogenesis in primary embryonic cells
or in vivo, it will be interesting to search for the possible
oncogenes cooperating with AdoMetDC.
Intracellular signaling is mediated by networks of inter-
acting proteins that govern various cellular processes. One
of the best characterized signal transduction pathways is
the Ras-Raf-MAPK route, which appears to be important
in the regulation of cell growth, differentiation, and pro-
tection against apoptosis (Seger and Krebs, 1995). Many
oncogenes are known to encode proteins along this path-
way or to require elevated Erk1/Erk2 activity for their
transforming activity (Su and Karin, 1996; Ip and Davis,
1998), suggesting an important role for these MAPKs in
transformation. However, we did not detect any constitu-
tive activation of Erk1 and Erk2 in the AdoMetDC-over-
expressing cells, indicating that they cannot be responsible
for the maintenance of AdoMetDC-induced transforma-
tion. This is consistent with the idea that activation of Erks
Figure 6. The expression of
DN JNK1, DN SEK1, and
c-Jun (TAM67) mutant pro-
teins and inhibition of c-Jun
phosphorylation by DN
JNK1 and DN SEK1. (A and
B) Western blot analyses of
the cell lysates for the ex-
pression of the mutant pro-
teins. Note that there are
multiple c-Jun TAM67 bands
(marked with a bracket), as
reported earlier (Brown et
al., 1994). (C) Western blot
analysis showing the inhibi-
tion of c-Jun phosphoryla-
tion in Amdc-s cells trans-
fected with DN JNK1 and
DN SEK1.The Journal of Cell Biology, Volume 151, 2000 808
is not essential for the transformed phenotype or prolif-
eration of all cell types, as recently suggested for the
c-Ha-ras-, v-src-, and ODC-transformed cells (Paasinen-
Sohns and Hölttä, 1997), as well as other transformations
(Samuels et al., 1993; Khosravi-Far et al., 1995; Raitano et
al., 1995; Alessandrini et al., 1996; Attar et al., 1996; Greu-
lich et al., 1996; Stofega et al., 1997).
Amdc-s cells showed a constitutive activation of JNKs,
which belong to the MAPK superfamily (Su and Karin,
1996; Ip and Davis, 1998). The JNKs were first identified
as protein kinases activated by various stress treatments,
but a low level of JNK activation has been observed also
after growth factor stimulation (Su and Karin, 1996; Ip and
Davis, 1998). On the other hand, activation of JNK and
concurrent inhibition of the Erk pathway have recently
been associated with apoptosis (Xia et al., 1995), the in-
duction of which is suggested to be determined by the du-
ration of JNK activity (Chen et al., 1996). However, this is
not the case with the AdoMetDC-transformed NIH3T3
and Rat-1 cells, which do not show any apoptotic features
(data not shown) and are actively proliferating. Likewise,
activation of JNK has been found to be associated with
transformation by the ras, met, v-crk, and bcr-abl onco-
genes (Raitano et al., 1995; Clark et al., 1997; Rodrigues et
al., 1997; Tanaka et al., 1997). Constitutive activation of
JNK in Amdc-s cells was accompanied by a persistent
phosphorylation of the transactivation domain of c-Jun on
Ser73. These results, together with the observed morpho-
logical reversion by the DN SEK1 and DN JNK1 mutants,
which inhibit JNK activation and c-Jun phosphorylation,
support an important role for the JNK-c-Jun pathway in
transformation of these cells. In addition, the accumula-
tion of multinucleated cells suggests that activation of
c-Jun may also be of importance in the regulation of cyto-
kinesis. Interestingly, the Amdc-as1spd cells also dis-
played a moderate increase in c-Jun phosphorylation, de-
spite the lack of JNK activation.
Phosphorylation of c-Jun on Ser63 and Ser73 has been
found to stimulate the transcriptional activity of c-Jun,
without affecting its DNA-binding activity (Smeal et al.,
1991, 1992). Ser73 is the major site of phosphorylation and
crucial for the transcriptional activity of c-Jun (Su and
Karin, 1996). Our finding of the constitutively elevated
phosphorylation of c-Jun on its NH2-terminal Ser73 in
vivo in the Amdc-s and Amdc-as1spd cells raises the pos-
sibility that transactivation by c-Jun, or some other func-
tion mediated by the transactivation domain, is important
for the transforming ability of AdoMetDC. The transacti-
vation domain of c-Jun was found to be essential for the
transformed phenotype, as transfection of the dominant-
negative Jun mutant TAM-67 reversed the morphology of
Amdc-s and Amdc-as1spd cells to normal. The present
data are the first to indicate that the polyamine biosyn-
thetic enzymes, and thereby polyamines that are essential
for growth, may require the c-Jun transcription factor for
eliciting their cellular responses. It is now evident that the
signal pathways initiated by many different oncogenes,
such as ras, src, mos, fos, and myc (Rapp et al., 1994;
Johnson et al., 1996), involve c-Jun activation, which may
be mediated, at least in part, by its phosphorylation. As
c-Jun is a component of the AP-1–transcription factor
complex, which can also contain other Jun family mem-
bers (JunB and JunD) and different Fos family members
(c-Fos, Fra-1 and Fra-2), or form a complex with ATF-2 or
Maf (Karin et al., 1997), it is possible that the complex for-
mation or the possible phosphorylation of other proteins is
of importance for transformation, as well. Besides, it has
been demonstrated that c-Jun can recruit JNK to the com-
plex to phosphorylate other substrates via heterodimeriza-
tion (Kallunki et al., 1996). Furthermore, though the cur-
rent opinion is that the Jun members are phosphorylated
by JNKs and the Fos members by Erk1/Erk2 (Davis, 1994;
Su and Karin, 1996), it is possible that there could be an
unknown kinase capable of phosphorylating both family
members. Indeed, we have detected an Erk- and JNK-
independent phosphorylation of c-Jun in ras- (Paasinen-
Sohns and Hölttä, 1997) and Amdc-as- (this study)
transformed cells. Correspondingly, an Erk- and JNK-
independent, transformation-specific phosphorylation of
FosB has been reported (Skinner et al., 1997).
Taken together, this study shows for the first time that
expression of AdoMetDC, either in sense or antisense ori-
entation, can induce tumorigenic transformation. To
our knowledge, this is the first example of a protein
whose overexpression or the block of synthesis can lead
to transformation. These data suggest that the levels
of AdoMetDC must be carefully regulated in order
not to predispose the cells to transformation. An interest-
ing finding is the observed high invasive capacity of the
AdoMetDC-transformed cells, which may open a new av-
enue in the studies of cancer cell spreading. In fact, inhibi-
tion of AdoMetDC has been reported to inhibit metastasis
of transplanted melanoma cells (Gutman et al., 1995). The
AdoMetDC sense, but not the antisense, expressors exhib-
ited activation of JNK. However, both transformations
converged on phosphorylation of c-Jun on its transacti-
vation domain. Since the expression of the dominant-
negative mutant of Jun, TAM-67, reverted both the
AdoMetDC sense– and antisense–induced transforma-
tions, it is tempting to speculate that the phosphorylation
of c-Jun, or specific AP-1 components, would be an impor-
tant point of convergence in the transforming action of
AdoMetDC and many other oncogenes. This idea is fur-
ther supported by our recent preliminary studies of Amdc-s
and Amdc-as1spd cells transfected with c-Jun mutants
with Ser63 and Ser73 mutated to alanines (our unpub-
lished data together with Dr. D. Bohmann). These phos-
phorylations could lead to novel activating interactions
with the basal transcription machinery or with other pro-
teins, or change the affinity of the transcription factors for
their cognate DNA motifs. Interestingly, the AdoMetDC-
transformed cells did not exhibit a significant increase in
transcription from a consensus tetradecanoyl phorbol ace-
tate–responsive element (TRE)–containing reporter con-
struct (col-TREx5/TK-CAT) (Angel et al., 1987) (our un-
published data). Whether this indicates that the number of
genes relevant for transformation is smaller than the num-
ber of genes normally regulated by AP-1 or the transfor-
mation-specific genes having a somewhat different AP-1
sites than col-TREx5 remains to be seen. Significantly, a
recent report (Young et al., 1999) supports this idea that
only a subset of AP-1–dependent genes, inhibited by
TAM67 expression, are involved in tumor promotion.
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